<DOC>
	<DOCNO>NCT01473563</DOCNO>
	<brief_summary>The main purpose study answer follow research question : - Can pemetrexed administer safely participant 's home , use treatment procedure hospital set ? - Will participant satisfy home care ? - How might impact participant 's quality life ? - What require medical resource need give pemetrexed home setting ?</brief_summary>
	<brief_title>A Study Home Administration Pemetrexed Maintenance Treatment Advanced Nonsquamous Non-Small Cell Lung Cancer ( NSCLC )</brief_title>
	<detailed_description />
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Carcinoma , Non-Small-Cell Lung</mesh_term>
	<mesh_term>Pemetrexed</mesh_term>
	<criteria>Have histological cytological diagnosis NSCLC define nonsquamous cell histology . Squamous cell and/or small cell histology permit . Mixed NSCLC tumor categorize predominant cell type . NSCLC tumor otherwise specify regard histology subclassified squamous , adenocarcinoma , large cell histology categorize nonsquamous Have Stage IIIB ( amenable curative treatment ) Stage IV NSCLC prior induction therapy define American Joint Committee Cancer ( AJCC ) Staging Criteria Lung Cancer Have complete 4 induction cycle platinumbased doublet therapy ( type discretion physician ) treatment advanced disease . Have progress 4 cycle induction therapy . Documented radiographic evidence tumor response must occur end Cycle 4 induction therapy within 3 week receive first cycle study drug [ see Response Evaluation Criteria Solid Tumors ( RECIST ) , version ( v ) 1.1 ] Receive onstudy treatment earlier 21 day later 42 day Cycle 4 Day 1 induction therapy Have Performance Status ( PS ) 0 1 Eastern Cooperative Oncology Group ( ECOG ) scale Meet follow guideline participant receive prior radiation therapy : Previous radiation therapy allow &lt; 25 % bone marrow , limited must include whole pelvis radiation Participants must recover toxic effect treatment prior study enrollment ( except alopecia ) Participants received palliative chest ( word , thoracic skeleton include dorsal spine ) palliative extrathoracic radiotherapy preexist lesion allow enrolled trial Have adequate organ function , include : Adequate bone marrow reserve : absolute neutrophil count ( ANC ) ( segmented band ) &gt; =1.5x109/Liter ( L ) , platelets &gt; =100x109/L , hemoglobin &gt; =9 gram per deciliter ( g/dL ) Hepatic : bilirubin &lt; =1.5 x upper limit normal ( ULN ) alkaline phosphatase ( ALP ) , aspartate aminotransferase ( AST ) , alanine aminotransferase ( ALT ) &lt; =3.0 x ULN ( ALP , AST , ALT &lt; =5.0 x ULN acceptable liver tumor involvement Renal : calculated creatinine clearance ( CrCl ) &gt; =45 milliliter per minute ( mL/min ) base original weightbased Cockcroft Gault formula Are willing comply follow contraceptive criterion : Females must surgically sterile , postmenopausal must negative serum urine pregnancy test within 7 day prior first dose study drug Males females reproductive potential : Must agree use reliable method birth control study 6 month follow last dose study drug Have estimate life expectancy least 12 week Have give write informed consent/assent prior studyspecific procedure Are willing comply home delivery administration family close environment support willing comply home delivery administration Are currently enrol , discontinue within last 30 day , clinical trial involve investigational product approve use drug device ( pemetrexed use study ) , concurrently enrol type medical research judge scientifically medically compatible study Have previously complete withdrawn study Have serious concomitant systemic disorder ( example , active infection include human immunodeficiency virus ) Have serious cardiac condition , myocardial infarction within 6 month , angina , heart disease , define New York Heart Association Class III IV Have symptomatic central nervous system ( CNS ) malignancy metastasis ( screen require ) . Participants treat CNS metastasis eligible study currently receive corticosteroid and/or anticonvulsant least 1 week start study treatment disease asymptomatic radiographically stable Are receive concurrent administration antitumor therapy Have second primary malignancy judgment investigator sponsor may affect interpretation result Are unable interrupt aspirin nonsteroidal antiinflammatory agent , aspirin dose â‰¤1.3 gram per day , 5day period ( 8day period longacting agent , piroxicam ) Are unable unwilling take folic acid vitamin B12 supplementation Are unable unwilling take corticosteroid Are pregnant lactate Have receive recent ( within 30 day enrollment ) receive concurrent yellow fever vaccination</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2014</verification_date>
</DOC>